Skip to main content
Contact Us
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
CDMO Intelligence
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Sepracor
Evaluate
September 03, 2012
Dainippon takes aim at Spiriva with Elevation buy
January 18, 2011
Big pharma continues M&A spending spree in 2010
October 01, 2010
Novo leads big pharma recovery in third quarter as Roche tumbles
July 01, 2010
Big pharma continues to struggle in first half, Indian generics consolidate gains
May 04, 2010
Dainippon receives an unwelcome knock back to Stedesa
April 09, 2010
Event – Dainippon’s Stedesa PDUFA unlikely to cause ripples in epilepsy market
April 01, 2010
Modest big cap winners and losers in first quarter 2010
March 19, 2010
Somaxon wins approval for Silenor and hunt for partner begins
March 05, 2010
Event - Somaxon facing dream or nightmare PDUFA decision
February 08, 2010
Event - Milestones from Exalgo approval will boost CombinatoRx's fortunes
November 26, 2009
Event - Somaxon awaiting decision that could wake it from slumber
Load More
Latest Reports
July 27, 2023
H1 Round Up: The haves and the have-nots
July 21, 2023
ADA/EASL eBook
Editor's Picks
July 03, 2023
Astrazeneca and Daiichi’s big reveal disappoints
July 13, 2023
Pharma finds a way to gain weight
July 03, 2023
Protagonist investors flake as psoriasis pill disappoints
June 29, 2023
Approaching datasets for big pharma
June 27, 2023
Nkarta goes back to basics